Pharma pay-for-delay concerns up again in Europe
This article was originally published in SRA
The number of patent settlement deals signed between originator pharma companies and generics manufacturers that may violate EU anti-competition rules tripled in 2011 over the previous year, according to the European Commission's third monitoring report1.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.